What Is Carcinoid Syndrome? A Critical Appraisal of Its Proposed MediatorsMulders MCF, de Herder WW, Hofland J.Endocr Rev. 2024 May 7;45(3):351-360.
doi: 10.1210/endrev/bnad035
Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks.Mullen N, Curneen J, Donlon PT, et al.
Endocr Rev. 2024 Jan 4;45(1):125-170.
doi: 10.1210/endrev/bnad026
Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia
Kyriakie Sarafoglou, Mimi S Kim, Maya Lodish, et al.
N Engl J Med. 2024 Jun 2.
doi: 10.1056/NEJMoa2404655
Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline
Eystein S Husebye, Frederik Castinetti, et al.
Eur J Endocrinol. 2022 Oct 25;187(6):G1-G21.
https://doi.org/10.1530/EJE-22-0689
Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement
Margaret C S Boguszewski, Cesar L Boguszewski , et al.
Eur J Endocrinol. 2022 Apr 21;186(6):P35-P52.
https://doi.org/10.1530/EJE-21-1186
Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop
John P Bilezikian 1, Aliya A Khan, et al.
J Bone Miner Res. 2022 Nov;37(11):2293-2314.
https://doi.org/10.1002/jbmr.4677
Comentarios recientes